RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Double-Barreled attack: stem cell transplant plus CAR-T shows promise for Hard-to-Treat lymphoma
Disease control CompletedThis completed study tested a two-step approach for people with relapsed or refractory B-cell non-Hodgkin's lymphoma. First, patients received a stem cell transplant using their own cells, followed by CAR-T cell therapy. The goal was to see if this combination could improve how l…
Matched conditions: RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA
Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New combo tackles tough lymphoma
Disease control CompletedThis study tested a new combination treatment for people with a type of blood cancer (B-cell non-Hodgkin's lymphoma) that did not respond to standard therapies. The treatment combined a drug (XPO-1 inhibitor) with specially engineered immune cells (CAR-T cells). The goal was to s…
Matched conditions: RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC